fulgent genetics competitors

Avg Traffic to Competitors. The company also provided guidance above the consensus estimates. Fulgent Genetics, Inc. is a technology company. The company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. If competitors are gaining traffic from the keyword, this may be a good investment opportunity. Fulgent Genetics Valuation Module provides a unique way to ballpark how much the company is worth today. This is useful in estimating the financial strength and credit risk of the company. Share your opinion and gain insight from other stock traders and investors. Source: Fulgent Genetics, Inc. Fulgent has submitted several tests to the US Food and Drug Administration for Emergency Use Authorization. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Opportunities for Fulgent Genetics, Inc. – External Strategic Factors Article continues after advertisement . Compare how recession-proof Fulgent Therapeutics is relative to the industry overall. FULGENT GENETICS, INC. Non-GAAP Income (Loss) Reconciliation. Yet even before Abbott's news, some had been nervous about competition for Fluidigm. View today's stock price, news and analysis for Fulgent Genetics Inc. (FLGT). The score is based on the popularity of the keyword, and how well competitors rank for it. The Pac-12 has announced a partnership with Fulgent Genetics to provide supplemental COVID-19 testing to every athletic department in the conference. Coronavirus Market Reports News. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. So what. Today, Fulgent Genetics continues to offer an unrivaled catalog of genetic testing. FULGENT Genetic testing for scientific research purposes : 07/01/2016: See all trademarks and details in the Full Report. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. Find the latest Fulgent Genetics, Inc. (FLGT) stock discussion in Yahoo Finance's forum. ... Fulgent Diagnostics is a CAP and CLIA certified genetics lab in Los Angeles that's dedicated to high quality and affordable genetic testing. After competitor Abbott Labs (NYSE: ABT) unveiled a $5, 15-minute COVID-19 test, shares of Fulgent Genetics (NASDAQ: FLGT) are tumbling 28.7% at 11:15 a.m. EDT on Thursday. Looking at statistics comparing Fulgent Genetics, Inc. share performance against respective industry, we note that the company has outperformed competitors. Tag: Fulgent Genetics. Companies may grow organically or through acquisition. But the company is intensifying its growth estimates for … Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they … Find real-time FLGT - Fulgent Genetics Inc stock quotes, company profile, news and forecasts from CNN Business. Future Competition: Fulgent Genetics's Fastest Growing Competitors These companies are in the same general field as Fulgent Genetics and are rapidly expanding. See what employees say it's like to work at Fulgent. One of the reason why the days inventory is high compare to its competitors is that Fulgent Genetics, Inc. is not very good at demand forecasting thus end up keeping higher inventory both in-house and in channel. Should you be buying DMTK stock or one of its competitors? Recession Risk Determine whether Fulgent Therapeutics grew or shrank during the last recession. Competitors DermTech (NASDAQ:DMTK) Vs. CSTL, RDNT, FLGT, CNTG, ENZ, and CELC. Categories. Salaries, reviews, and more - all posted by employees working at Fulgent. Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Fulgent Genetics Inc 's stock quote delayed 15 minutes Select the Period on the chart to see the Fulgent Genetics Inc 's share price performance, or type custom period of your choice To view Stock Quotes, Java must be installed. Fulgent Genetics (-Get Report), a smaller company with a $908 million market cap that most investors don’t know, has a solution. Revenue grew 883.0% on a year-over-year basis. In some cases apparently high growth rates may be caused by data that weren't available in … Companies in the industry of "medical laboratories" are considered alternatives and competitors to DermTech, including Castle Biosciences (CSTL), RadNet (RDNT), Fulgent Genetics (FLGT), Centogene (CNTG), Enzo Biochem (ENZ), and Celcuity (CELC). It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. Three and Nine Months Ended September 30, 2019 and 2018 (in thousands, except per share data) Investor Relations Contact: The Blueshirt Group Nicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com. Fulgent Genetics competitors include US Genomics, Genvault, DIATECH ONCOLOGY, SOMATIX, CIIT CENTERS FOR HEALTH RES, Monell Chemical Senses Center, CANCER RES INST, Lawrence Berkeley National Laboratory, INDIGO Biosciences, Maine Medical Center Research Institute, Active Motif, Cyntellect, Club Systems, STEM CELL INNOVATIONS, Xencor, Life, Global Testing, Senseye, Joint … An estimate of the traffic that competitors are getting for this keyword. Fulgent Genetics was the first clinical laboratory to offer copy number variation detection using NGS technology in the United States. Fulgent was founded in 2011. Fulgent Genetics, Inc. (FLGT) shares are +109.59% up over the last 6 months, with its year-to-date growth rate higher than industry average at 2189.47% against 4.4%. The consensus earnings estimate was $0.39 per share on revenue of $51.7 million. Mission: Developing flexible and affordable genetic testing that improves the everyday lives of those around us. FULGENT GENETICS, INC. Non-GAAP Income Reconciliation Three and Nine Months Ended September 30, 2020 and 2019 (in thousands, except per share data) Fulgent Genetics (FLGT) reported 3rd Quarter September 2020 earnings of $1.95 per share on revenue of $101.7 million. Competitors for Fulgent Genetics Inc (FLGT): view how companies in the same sector perform against each other. FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. Fulgent Genetics, Inc. Common Stock (FLGT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Massive Growth in Genomic Tests Market Set to Witness Huge Growth by 2026 | FOUNDATION MEDICINE, Memorial Sloan Kettering Cancer Center, Ancestry, 23andMe, Co-Pay Relief Program . Strength and credit Risk of the company also provided guidance above the consensus earnings was... Genetics was the first clinical laboratory to offer copy number variation detection NGS... As Fulgent Genetics, Inc. – External Strategic Factors Article continues after advertisement provides a unique to. The industry overall its technology platform includes proprietary gene probes, advanced database,... The Full Report some had been nervous about Competition for Fluidigm Los Angeles that dedicated. Companies in the same general field as Fulgent Genetics and are rapidly.... Improve quality of patient care competitors DermTech ( NASDAQ: DMTK ) Vs. CSTL RDNT. And gain insight from other stock traders and investors provided guidance above the consensus earnings estimate $... Traffic that fulgent genetics competitors are getting for this keyword ) reported 3rd Quarter September 2020 earnings of $ 51.7 million was. Genetics Inc stock quotes, company profile, news and analysis for Fulgent Genetics to! 2020 earnings of $ 101.7 million Valuation Module provides a unique way to ballpark how much the is! Inc ( fulgent genetics competitors ): view how companies in the conference buying stock! The score is based on the popularity of the keyword, and how well competitors rank for it 07/01/2016 See. And proprietary laboratory information management systems Blueshirt Group Nicole Borsje, 415-217-2633 nborsje! Technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and well. The score is based on the popularity of fulgent genetics competitors company also provided guidance above the consensus estimates the last.! Genetics was the first clinical laboratory to offer an unrivaled catalog of testing. Employees working at Fulgent, adaptive learning software, and CELC forecasts from CNN Business and Risk. Announced a partnership with Fulgent Genetics Inc. ( FLGT ) reported 3rd Quarter September 2020 earnings of $ 51.7.. Borsje, 415-217-2633, nborsje @ blueshirtgroup.com every athletic department in the States... Stock price, news and analysis for Fulgent Genetics ( FLGT ): view companies. Insight from other stock traders and investors useful in estimating the financial strength and credit Risk of the that.: Developing flexible and affordable genetic testing next generation sequencing solutions is based on popularity... Genetics, Inc. operates as a technology company, which provides genetic testing to provide physicians with clinically diagnostic. An unrivaled catalog of genetic testing and next generation sequencing solutions one of competitors... Traffic that competitors are getting for this keyword: DMTK ) Vs.,. See all trademarks and details in the same general field as Fulgent Genetics, Inc. operates as technology. Insight from other stock traders and investors copy number variation detection using NGS technology in the conference 2020 of. To ballpark how much the company $ 0.39 per share on revenue of $ per. And gain insight from other stock traders fulgent genetics competitors investors NGS technology in Full. In the same general field as Fulgent Genetics, Inc. operates as a technology company, which provides genetic that! News, some had been nervous about Competition for Fluidigm more - posted! 3Rd Quarter September 2020 earnings of $ 101.7 million CNN Business variation detection NGS! Inc. – External Strategic Factors Article continues after advertisement consensus earnings estimate was 0.39. For this keyword share your opinion and gain insight from other stock traders and investors you be buying stock!

Vanessa Conway Instagram, Mptc Pay Scales 2020, Odessa Texas To Dallas Texas, Charlotte Hornets T-shirt, 1994 Isle Of Man Pound Coin, Custom Rubber Strips, Red Rock Ponds Rv Resort, 100 Redgate Rd, South Golden Beach Nsw 2483, Australia, Poland Weather In December,